Johnson & Johnson CD38 monoclonal antibody new indication approved in China, sales of 4.19 billion U.S. dollars in 2020
Kangfang Bio-PD-1/CTLA-4 Dual Antibody Approved Global Phase 3 Clinical First-line Treatment for Advanced Cervical Cancer
Will I still be infected if I detect antibodies after being injected with the new crown vaccine?
FDA accelerates approval of GlaxoSmithKline PD-1 antibody to treat patients with specific endometrial cancer
; the world's first new indication of CD38 monoclonal antibody is about to be approved in China|Tumor News
The FDA today accelerated the approval of the first antibody conjugate drug targeting CD19, and it has been approved for clinical trials in China
FDA accelerates approval of the first CD19-targeted antibody conjugate drug has been clinically approved in China
GM-CSF monoclonal antibody combined with Yescarta, all CRS events are less than or equal to grade 3!
The PD-1 antibody purchased by GSK for US$5.1 billion was approved for listing in the U.S. and EU at the same time | Yimai Meng broke the news
; PD-1/CTLA-4 dual antibody was approved to carry out a phase III clinical trial for the first-line treatment of advanced cervical cancer|Tumor News
ASM Biotech declares the third domestic CD20/CD3 double antibody
Roche/Regeneron COVID-19 antibody cocktail therapy drastically reduces hospitalizations/...
Amgen's bispecific antibody AMG 570 is approved in China...
FDA revokes emergency use authorization for Eli Lilly's new crown antibody drug
In 2020, the global antibody drug market will exceed $150 billion, and the five major target "cornucopia" will be released
All aspects of CD30 target: ADC is a hit, but red anti-double antibody has no fruit yet. CART research and development is fierce...
Qilu Pharmaceutical has introduced a "first-in-class" antibody pair...
BeiGene TIGIT monoclonal antibody BGB-A1217 injection was approved for clinical use
Kangfang Bio-IL-4R monoclonal antibody was approved for clinical indication for moderate to severe atopic dermatitis
All-round view of the CD30 target: ADC is a hit, but the red double antibody has no fruitful CAR...